CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 464,714	$ 132,149
Marketable securities	101,547	223,185
Trade receivable, net	156,769	120,111
Inventory	58,329	39,563
Prepaid expenses and other current assets	119,337	88,398
Total current assets	900,696	603,406
Property and equipment, net	11,258	9,340
Equity method investment	0	1,176
Intangible assets, net	58,226	39,087
Other assets	32,979	33,966
Total assets	1,003,159	686,975
Current liabilities:
Accounts payable	64,571	48,476
Accrued expenses and other current liabilities	268,720	166,630
Current portion of mandatorily redeemable preferred shares	62,500	62,500
Total current liabilities	395,791	277,606
Long-term debt	270,756	267,458
Liability related to sale of future royalties, net	339,020	328,350
Mandatorily redeemable preferred shares, net	122,119	111,591
Derivative liability	14,400	14,190
Obligation to perform R&D services	60,530	932
Other long-term liabilities	18,698	19,037
Total liabilities	1,221,314	1,019,164
Commitments and contingencies
Contingently redeemable non-controlling interests	60,000	60,000
Shareholders’ deficit:
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 65,066,468 and 60,436,876 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	1,604,021	1,249,547
Additional paid-in capital	123,731	98,938
Accumulated other comprehensive income	409	314
Accumulated deficit	(2,004,137)	(1,739,169)
Total shareholders’ deficit attributable to Biohaven Pharmaceutical Holding Company Ltd.	(275,976)	(390,370)
Non-controlling interests in consolidated subsidiaries	(2,179)	(1,819)
Total shareholders' deficit	(278,155)	(392,189)
Total liabilities and shareholders’ deficit	$ 1,003,159	$ 686,975